Fiche du document
- doi: 10.1016/j.smim.2023.101727
- issn: 1044-5323
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.smim.2023.101727
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/36764021
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1096-3618
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_6B56B0492D5F8
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
Scientific research Science research Science--Research People Man Humanity (Human beings) Human race Mankind Homo sapiens Humankind HumansCiter ce document
I.E. Shapiro et al., « The impact of immunopeptidomics: From basic research to clinical implementation. », Serveur académique Lausannois, ID : 10.1016/j.smim.2023.101727
Métriques
Partage / Export
Résumé
The immunopeptidome is the set of peptides presented by the major histocompatibility complex (MHC) molecules, in humans also known as the human leukocyte antigen (HLA), on the surface of cells that mediate T-cell immunosurveillance. The immunopeptidome is a sampling of the cellular proteome and hence it contains information about the health state of cells. The peptide repertoire is influenced by intra- and extra-cellular perturbations - such as in the case of drug exposure, infection, or oncogenic transformation. Immunopeptidomics is the bioanalytical method by which the presented peptides are extracted from biological samples and analyzed by high-performance liquid chromatography coupled to tandem mass spectrometry (MS), resulting in a deep qualitative and quantitative snapshot of the immunopeptidome. In this review, we discuss published immunopeptidomics studies from recent years, grouped into three main domains: i) basic, ii) pre-clinical and iii) clinical research and applications. We review selected fundamental immunopeptidomics studies on the antigen processing and presentation machinery, on HLA restriction and studies that advanced our understanding of various diseases, and how exploration of the antigenic landscape allowed immune targeting at the pre-clinical stage, paving the way to pioneering exploratory clinical trials where immunopeptidomics is directly implemented in the conception of innovative treatments for cancer patients.